Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Differentiation of arterioles and capillaries in human blood vessel organoids with decellularized splenic matrix

Zheng F., Chen Y., Xue G., Xu J., Wang Z., Yang G.

Animal Study on Cardiovascular Disease, published in Bioact Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Bioact Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42232747
PMCID
PMC13223969
DOI
10.1016/j.bioactmat.2026.05.021

Abstract (original English)

Vascular organoids show great promise for promoting angiogenesis post-myocardial infarction, but current organoid culture methods only form capillaries in vitro , while relying on Matrigel faces challenges due to its undefined composition and potential immune reactions, which hinder clinical translation. To address this issue, a splenic extracellular matrix-derived thermoresponsive hydrogel (SpGel) with type I collagen was developed. This matrix has defined components, avoids the immune response triggered by viruses in Matrigel, and demonstrates the ability to enhance arterioles and capillary differentiation in blood vessel organoids. The gelation time of SpGel/col-I was comparable to that of typical Matrigel/col-I matrix. Additionally, SpGel/col-I significantly boosted angiogenesis of human blood vessel organoids compared to the Matrigel/col-I group. Single-cell sequencing revealed significant upregulation of ITGA5 and ITGB1 in the endothelial cell population within the SpGel/col-I group, and the increase in endothelial and mural cell differentiation was mainly associated with the VEGF and PDGFB signaling pathways. To verify the in vivo reparative effects, SpGel/col-I with hBVOs were co-transplanted into a myocardial infarction animal model and showed improved cardiac function, reduced myocardial fibrosis, and enhanced neovascularization. In summary, we successfully improved t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research